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INSIGHT

BONE HORMONES

Survival of the glycosylated
Osteocalcin is a bone matrix protein that acts like a hormone when it
reaches the blood, and has different effects in mice and humans.
HARRY C BLAIR AND PAUL H SCHLESINGER
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one tissue is constantly being created
and replaced in a process called remodeling. This involves cells called osteoblasts making bone and others cells called
osteoclasts taking up the various minerals and
proteins released from the degraded bone and
discharging them into the blood (Figure 1).
Osteocalcin is a protein found in bone tissue
and is abundantly present in amounts equimolar
to collagen – the structural protein of bone.
Once absorbed by osteoclasts, osteocalcin
displays variable carboxylation (the adding of a
carboxyl acid group to the protein sequence)
and is cleaved at various sites during its release.
The osteocalcin molecules that reach the
blood are a complex family of distinctive small
peptides, most of which are less than 1000 kDa
in weight (Blair et al., 1986). The family of discharged peptides include mixtures of intact or
cleaved osteocalcin (Ivaska et al., 2004) and
partially uncarboxylated protein (Poser and
Price, 1979; Cairns and Price, 1994). These
molecules behave like hormones, traveling to
other organs in the body – such as the pancreas
and liver – where they help to regulate metabolic processes (Tsuka et al., 2015).
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It is widely posited that bone acts as endocrine organ that contributes to metabolic
regulation (Dirckx et al., 2019). For example,
knocking out the gene for osteocalcin in mice
has been shown to impair glucose tolerance, to
lead to increase bone formation, and to reduce
testosterone production and muscle mass. However, these metabolic changes are variable and
do not occur in all mouse models
(Komori, 2020).
The G-protein receptor that osteocalcin binds
to can also interact with numerous other ligands,
such as calcium and steroids, which may be
responsible for these differing observations
(Pi et al., 2005). Furthermore, other hormones
that bind to G-protein receptors, such as follicle
stimulating hormone, have been found to activate receptors not on their target organ, and
cause additional, unexpected effects (Sun et al.,
2006). Together, this demonstrates the challenges associated with studying the function of
osteocalcin, and why there is still a great deal to
learn about the various roles of osteocalcin in
mammals, including humans.
To coordinate metabolism in diverse tissues,
the modified osteocalcin needs to be maintained
at high levels in the blood and not be immediately removed by the kidney’s filtration system
and discharged in the urine. Now, in eLife,
Mathieu Ferron and co-workers from the Montreal Clinical Research Institute, the University of
Montreal, the University of Copenhagen and
McGill University – including Omar Al Rifai as
first author – report how osteocalcin in mice is
able to survive for longer in the blood than
human osteocalcin (Al Rifai et al., 2020).
The team found that mouse osteocalcin
undergoes an additional modification, which
attaches a small sugar group called an O-glycan
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Figure 1. How osteocalcin is synthesized and released
into the blood. The protein osteocalcin (red dots)
resides in the bone matrix with collagen (green) and
other matrix proteins integrated into mineralized bone.
Bone tissue is broken down by cells called osteoclasts
(shape outlined in blue), and left-over proteins –
including osteocalcin – are partially degraded and
discharged into the blood.

to a serine residue in the protein. Al Rifai et al.
discovered that this sugar group prevented
osteocalcin from being degraded by enzymes in
the blood. Human osteocalcin was found to
have a tyrosine residue at this site: however,
when this was replaced with a serine residue,
O-glycan groups were able to bind to the hormone and make it more stable, causing it to persist for longer in the blood. This difference in
stability is likely what causes mice to have 5–10
times more osteocalcin in their blood than
humans.
Much of what is known about the influence of
osteocalcin on metabolism has come from
experiments on mice. However, in addition to
having different levels of osteocalcin, the molecular biology of this hormone also differs
between humans and mice. In rodents, osteocalcin is coded by a cluster of three genes, two of
which
are
expressed
in
osteoblasts
(Moriishi et al., 2020), whereas human osteocalcin is coded by a single gene (Celeste et al.,
1986).
Further work is needed to address other
aspects of how osteocalcin is processed and regulated in humans. Previous studies suggest that
levels of human osteocalcin are also regulated
by the rate at which osteoclasts break down the
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bone’s tissue, and inhibiting this process has
been found to reduce the amounts of osteocalcin in the blood by 30% (Zhou et al., 2020).
However, the degradation of bone might not be
the sole source of osteocalcin in humans (Figure 1), and some of our experiments suggest
that when levels of osteocalcin are low, cells
other than osteoblasts may also release moderate amounts of decarboxylated osteocalcin into
the blood; but this remains to be established.
This suggestion is supported by the fact that
while decarboxylation in osteoclasts has not
been fully studied, the process has been shown
to be acid driven in vitro, and therefore unlikely
to occur in osteoclasts (Poser and Price, 1979).
The findings of Al Rifai et al. demonstrate the
challenges involved in extrapolating results
about hormones and metabolism from mice to
humans. Further work is still needed to fully
understand the role of osteocalcin in humans,
and to gain a clearer understanding of how levels of this hormone are regulated.
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